Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jennifer ClarkMitchell Cancer Institute and Department of Pharmacology, University of South Alabama, Mobile, AL 36604, USA.
Robert W SobolMitchell Cancer Institute and Department of Pharmacology, University of South Alabama, Mobile, AL 36604, USA.ORCID 0000-0001-7385-3563
Millie M GeorgiadisXPose Therapeutics, Inc., San Carlos, CA 94070, USA.
John King-UnderwoodXPose Therapeutics, Inc., San Carlos, CA 94070, USA.
David V JobesXPose Therapeutics, Inc., San Carlos, CA 94070, USA.
Caleb ChangDepartment of BioSciences, Rice University, Houston, TX 77251, USA.
Yang GaoDepartment of BioSciences, Rice University, Houston, TX 77251, USA.ORCID 0000-0002-4037-0431
Ashley M DeaconXPose Therapeutics, Inc., San Carlos, CA 94070, USA.
David M WilsonXPose Therapeutics, Inc., San Carlos, CA 94070, USA.
Funding
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
A Systems Approach to Mapping the DNA Damage ResponseR01ES014811 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2005 to 2021
$8.6M
HOUSTON AREA MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008280 · NIGMS · RICE UNIVERSITY · PI WENSEL, THEODORE G · 1988 to 2023
$8.0M
Research Project 3P01ES028949 · NIEHS · FLORIDA GULF COAST UNIVERSITY · PI PARSONS, MICHAEL · 2018 to 2024
$3.8M
Novel approaches to enhance tumor cell cytotoxicity of alkylating agentsR01CA148629 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2010 to 2021
$3.4M
Investigating genetic ancestry influences on oral cavity and laryngeal cancer survival disparitiesR01CA238061 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI RAGIN, CAMILLE C., SOBOL, ROBERT W · 2019 to 2023
$3.4M
Measuring genomic DNA damage and DNA repair capacity in longitudinal population samples - a step towards precision preventionU01ES029518 · NIEHS · UNIVERSITY OF SOUTH ALABAMA · PI SOBOL, ROBERT W · 2018 to 2022
$2.7M
Rapid Hit Generation and Lead Elaboration for SARS-CoV-2 TherapeuticsR44GM132796 · NIGMS · ACCELERO BIOSTRUCTURES, INC. · PI DEACON, ASHLEY M. · 2018 to 2020
$2.0M
Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variabilityR44ES032522 · NIEHS · AMELIA TECHNOLOGIES, LLC · PI GEORGE, JAY, SOBOL, ROBERT W · 2021 to 2023
$1.9M
The Paternal Age Effect - Enhanced Germ Cell Mutagenesis Modulated by the TRP53/APE1/MDM2 Tumor Suppressor AxisR01AG069740 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KRAIG, ELLEN · 2020 to 2024
$1.8M
SON-mediated RNA splicing in glioblastomaR01CA236911 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHN, ERIN EUN-YOUNG · 2020 to 2024
$1.8M
Targeting the DNA repair enzyme apurinic/apyrimidinic endonuclease (APE1) to treat cancerR43CA254552 · NCI · XPOSE THERAPEUTICS, INC. · PI PELLICENA, PATRICIA · 2020 to 2020
The ability to quickly discover reliable hits from screening and rapidly convert them into lead compounds, which can be verified in functional assays, is central to drug discovery. The expedited validation of novel targets and the identification of modulators to advance to preclinical studies can significantly increase drug development success. Our SaXPy
Indexed as
DNA-Directed DNA PolymeraseDrug DiscoveryBinding SitesCrystallography, X-RayDNA-(Apurinic or Apyrimidinic Site) LyaseEndonucleasesY-Family DNA PolymerasesDNA-(Apurinic or Apyrimidinic Site) LyaseDNA-Directed DNA PolymeraseEndonucleasesRad30 proteinY-Family DNA PolymerasesAPE1cancer therapeuticsDNA damage responsefragment-based drug discoveryPol etaPOLHpolymerasesstructure-based drug discoverysynthetic lethalitytargeted protein degradationX-ray crystallography
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A New Drug Discovery Platform: Application to DNA Polymerase Eta and Apurinic/Apyrimidinic Endonuclease 1. · full record | OpenQuestion